Inovio Pharmaceuticals, Inc.
Company Snapshot: Inovio Pharmaceuticals, Inc.
Inovio is revolutionizing vaccines to prevent and treat today's cancers and challenging infectious diseases. Its SynCon vaccines, in combination with its proprietary electroporation delivery, are generating best-in-class immune responses, with therapeutic T-cell responses exceeding other technologies in terms of magnitude, breadth, and response rate. Human data to date have shown a favorable safety profile. Inovio's lead vaccine, a therapeutic against HPV-caused pre-cancers and cancers, is in phase II. Other phase I and preclinical programs target prostate, breast, and lung cancers as well as HIV, influenza, malaria and hepatitis. Partners and collaborators include Roche, the University of Pennsylvania, Merck, NIH, HIV Vaccines Trial Network, National Cancer Institute, U.S. Military HIV Research Program, University of Southampton, US Dept. of Homeland Security, University of Manitoba and PATH Malaria Vaccine Initiative.
- Jan 17 2018 Inovio’s Co-Founder along with its Lead Antigen Designer Named Among Top 20 Researchers With Most Granted U.S Patents for 2016
- Jan 9 2018 Inovio Pharmaceuticals and the Parker Institute for Cancer Immunotherapy Establish Clinical Development Collaboration To Evaluate Novel Cancer Immunotherapy Combinations
- Jan 8 2018 Inovio Receives Milestone Payment from MedImmune as MEDI0457 and Checkpoint Inhibitor Combination Trial in Head and Neck Squamous Cell Cancer Advances to Phase 2
- Jan 2 2018 Inovio Enters License and Collaboration Agreement with ApolloBio To Develop and Commercialize VGX-3100 in Greater China